The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in TROP2 expression in lung cancer patients receiving anticancer treatments.
 
Shota Omori
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD; Ono Pharmaceutical
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Koji Muramatsu
No Relationships to Disclose
 
Takuya Kawata
No Relationships to Disclose
 
Haruki Kobayashi
No Relationships to Disclose
 
Kazuhisa Nakashima
No Relationships to Disclose
 
Kazushige Wakuda
Honoraria - Boehringer Ingelheim; Taiho Pharmaceutical
 
Akira Ono
Honoraria - Boehringer Ingelheim; Chugai Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Tateaki Naito
Honoraria - Ono Pharmaceutical
 
Haruyasu Murakami
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Novartis (Inst); Quintiles (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Sugino
No Relationships to Disclose
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)